Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic Bets On Twelve In Transcatheter Mitral Valve Replacement Race

This article was originally published in The Gray Sheet

Executive Summary

The medtech giant is acquiring Twelve Inc. to expand its early-stage efforts in transcatheter mitral valve replacement.

You may also be interested in...



Starts & Stops: Medtronic's TMVR News Closes Big Month For Trial Announcements

Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial announcements, initiations, completions, and suspensions each month. This month's edition, covering a long list of device trial updates that occurred between Sept. 24 and Oct. 31, is headlined by Medtronic's APOLLO US pivotal trial of the Intrepid transcatheter mitral valve.

Business Briefs: Knee, Obesity Approvals, And A Deal Roundup

Key approvals for Stryker and Apollo Endosurgery, and deals by Boston Scientific, Illumina, Abbott and Lombard Medical.

Huma Secures EU MDR Approval For Medtech Software That Can Be Used In Any Disease

Huma Therapeutics has secured the first ever EU regulatory approval for a “disease agnostic” class IIb medtech software platform. CEO Dan Vahdat tells Medtech Insight how the product can be configured to monitor patients with any condition.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034166

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel